利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.057 秒)

    METHOD FOR PREDICTING THE RESPONSE TO CHEMOTHERAPY IN A PATIENT SUFFERING FROM OR AT RISK OF DEVELOPING RECURRENTBREAST CANCER
    4.
    发明申请
    METHOD FOR PREDICTING THE RESPONSE TO CHEMOTHERAPY IN A PATIENT SUFFERING FROM OR AT RISK OF DEVELOPING RECURRENTBREAST CANCER 审中-公开
    预防患者发生反应性癌症发生风险的患者反应的方法

    公开(公告)号：US20140228241A1

    公开(公告)日：2014-08-14

    申请号：US14235168

    申请日：2012-07-30

    申请人： Mathias Gehrmann ,  Karsten Weber ,  Ralf Kronenwett ,  Christoph Petry ,  Jan Christoph Brase

    发明人： Mathias Gehrmann ,  Karsten Weber ,  Ralf Kronenwett ,  Christoph Petry ,  Jan Christoph Brase

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q1/6809 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.

    摘要翻译： 一种在患有或有发生复发性肿瘤疾病，特别是乳腺癌风险的患者中预测化疗（包括新辅助化疗）的反应和/或益处的方法，所述方法包括以下步骤：（a）在 来自所述患者的肿瘤样品包括以下8个基因：UBE2C，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP的RNA表达水平，其指示对肿瘤的化学疗法的反应，或（b）在肿瘤中测定 来自所述患者的样品来自以下8个基因的RNA表达水平：UBE2C，BIRC5，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP; 指示对肿瘤的化学疗法的反应（c）在数学上组合所述组的基因的表达水平值，所述基因在肿瘤样品中测定以产生组合评分，其中所述组合评分预测所述应答和/或益处 的化疗。

    SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO CARDIOVASCULAR DISEASE
    5.
    发明申请
    SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO CARDIOVASCULAR DISEASE 审中-公开
    单核细胞多态性与心血管疾病的相关性相关

    公开(公告)号：US20080233582A1

    公开(公告)日：2008-09-25

    申请号：US12019651

    申请日：2008-01-25

    申请人： Monika Stoll ,  Gerd Assmann ,  Helmut Schulte ,  Werner Kroll ,  Stephan Schwers ,  Christoph Petry

    发明人： Monika Stoll ,  Gerd Assmann ,  Helmut Schulte ,  Werner Kroll ,  Stephan Schwers ,  Christoph Petry

    IPC分类号： C12Q1/68 ,  C07H21/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： The present invention provides SNPs, polymorphic variants, and haplotypes associated with cardiovascular disease. The invention also provides methods for detecting the SNPs, polymorphic variants, and haplotypes. The invention also provides methods for determining an individual's genotype with respect to one or more polymorphisms and/or haplotypes associated with cardiovascular disease. The invention further provides methods of determining whether an individual has or is susceptible to development or occurrence of a cardiovascular disease or event. The methods are useful for providing diagnostic and/or prognostic information, selecting therapeutic regimens, etc. The invention further provides reagents and kits for practicing the methods.

    摘要翻译： 本发明提供了与心血管疾病相关的SNP，多态变体和单体型。 本发明还提供了用于检测SNP，多态变体和单体型的方法。 本发明还提供了关于与心血管疾病相关的一种或多种多态性和/或单倍型确定个体基因型的方法。 本发明还提供了确定个体是否具有或易于发展或发生心血管疾病或事件的方法。 该方法可用于提供诊断和/或预后信息，选择治疗方案等。本发明还提供用于实施该方法的试剂和试剂盒。

    Reference sample for quality control in molecular diagnosis
    6.
    发明申请
    Reference sample for quality control in molecular diagnosis 审中-公开
    参考样品用于分子诊断中的质量控制

    公开(公告)号：US20130183710A1

    公开(公告)日：2013-07-18

    申请号：US13817208

    申请日：2011-07-18

    申请人： Elke Reifenberger ,  Petra Walter ,  Christoph Petry

    发明人： Elke Reifenberger ,  Petra Walter ,  Christoph Petry

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/68 ,  C12Q1/6837 ,  C12Q1/6851 ,  C12Q2565/501 ,  C12Q2545/114 ,  C12Q2545/113

    摘要： The present invention relates to a reference sample for quality control purposes in molecular diagnosis of biological samples, which reference sample comprises a mixture of cells from at least one reference cell line which exhibits a particular gene expression profile, and at least one type of lymphocytes. Furthermore, the invention relates to productions methods for such references samples as well as to methods of their use.

    摘要翻译： 本发明涉及用于生物样品分子诊断中的质量控制目的的参考样品，该参考样品包括来自显示特定基因表达谱的至少一个参考细胞系的细胞混合物和至少一种类型的淋巴细胞。 此外，本发明涉及这种参考样品的生产方法以及它们的使用方法。

    IN VITRO METHOD FOR DIAGNOSING TUMOR DISEASES
    8.
    发明申请
    IN VITRO METHOD FOR DIAGNOSING TUMOR DISEASES 审中-公开
    用于诊断肿瘤疾病的体外方法

    公开(公告)号：US20100247438A1

    公开(公告)日：2010-09-30

    申请号：US12731499

    申请日：2010-03-25

    申请人： Arne Hengerer ,  Andreas Kappel ,  Luis Lasalvia ,  Andrea Lichte ,  Thomas Mertelmeier ,  Sven Meyburg ,  Christoph Petry ,  Marcus Pfister ,  Martin Requardt

    发明人： Arne Hengerer ,  Andreas Kappel ,  Luis Lasalvia ,  Andrea Lichte ,  Thomas Mertelmeier ,  Sven Meyburg ,  Christoph Petry ,  Marcus Pfister ,  Martin Requardt

    IPC分类号： A61K49/00 ,  G01N33/53 ,  G01N33/573 ,  G01N33/48 ,  A61B1/00

    CPC分类号： G01N33/57488 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57473 ,  G01N2333/585 ,  G01N2333/70503 ,  G01N2333/96486

    摘要： An in vitro method is for diagnosing a tumor disease in a patient. In at least one embodiment, the method includes: (i) determining an IVD marker or an IVD marker panel in at least one biological sample of a patient, wherein the IVD marker has a high sensitivity to the tumor disease, (ii) determining the proportion of patients tested positive due to an adapted reference range of the IVD marker/IVD marker panel, wherein the reference range was adapted such that the number of individuals with false negative tests, the number of individuals with false positive tests and the number of individuals ultimately needing to be subjected to imaging diagnostics to clarify false negative and false positive results are balanced in respect of one another such that tumor screening can be carried out, possibly: (iii) deciding to carry out an imaging method specific to the respective tumor disease for clarifying possible false negative and/or false positive IVD results, or (iv) repeating stages (i) and (ii) after a defined time interval, or (v) carrying out an imaging method for imaging the tumor.

    摘要翻译： 体外方法是用于诊断患者的肿瘤疾病。 在至少一个实施方案中，该方法包括：（i）确定患者的至少一个生物样品中的IVD标记或IVD标记物组，其中IVD标记对肿瘤疾病具有高度敏感性，（ii）确定 由于IVD标记/ IVD标记物组的适应参考范围，患者的比例为阳性，其中参考范围被改编为使得具有假阴性测试的个体数量，具有假阳性测试的个体数量和个体数量 最终需要进行成像诊断以澄清假阴性和假阳性结果在彼此之间相互平衡，使得可以进行肿瘤筛选，可能：（iii）决定执行特定于各自肿瘤疾病的成像方法 用于澄清可能的假阴性和/或假阳性IVD结果，或（iv）在限定的时间间隔后重复阶段（i）和（ii），或（v）进行成像 肿瘤成像方法。